Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Cell Therapeutics announced it will report its second quarter 2026 financial results on August 6, 2026, after the market closes. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The company is a clinical-stage biotechnology firm focused on allogeneic cell therapies for serious medical conditions.

•2mo ago

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Lineage Cell Therapeutics announced that CEO Brian M. Culley will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit. The fireside chat, hosted by B. Riley analyst Mayank Mamtani, is scheduled for July 16, 2026, at the InterContinental Boston. Investors interested in scheduling one-on-one meetings with the management team are encouraged to contact their B. Riley representative.

•3mo ago

LCTX: 8-K · proxy statement

Lineage Cell Therapeutics reported the results of its annual shareholder meeting held on June 10, 2026. Shareholders elected all seven director nominees and ratified the appointment of Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2026. Shareholders also approved the executive compensation advisory vote (say-on-pay) with approximately 97% of votes cast in favor. The filing also disclosed that the company withdrew its application for a Clinical Trial award from the California Institute for Regenerative Medicine (CIRM) on June 9, 2026. The company stated that the withdrawal of the CIRM grant application does not impact the ongoing DOSED clinical study for its OPC1 therapy in spinal cord injury patients. This routine governance filing confirms board stability and continued clinical development without significant financial or operational disruption.

SEC 8-K•4mo ago

LCTX: 10-Q · periodic report

Lineage Cell Therapeutics, Inc. reported a net loss of $4.812 million for the three months ended March 31, 2026, compared to a net loss of $4.139 million for the same period in 2025. The company's total revenue increased by 15% to $1.725 million in the first quarter of 2026, driven by a $0.3 million increase in collaboration revenues from the WDI collaboration. The company's cash position as of March 31, 2026, was $35.939 million, down from $40.791 million at the end of 2025. The decrease in cash is primarily due to the net cash used in operating activities, which was $8.078 million for the quarter. Despite the net loss, the company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months. The company's pipeline includes several cell therapy programs, with OpRegen in Phase 2a development for the treatment of geographic atrophy secondary to dry-AMD, and ReSonance in preclinical development for auditory neuropathy. The company also announced the launch of the COR1 program for corneal endothelial disease, and the ILT1 initiative for islet cell manufacturing. The ongoing Israeli regional conflict and broader geopolitical tensions pose a risk to the company's operations, particularly given the significant presence of its workforce and manufacturing facilities in Jerusalem. However, as of the filing date, the company has not experienced any material disruptions.

SEC 10-Q•5mo ago

LCTX: 8-K · earnings release

On May 12, 2026, Lineage Cell Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026. The company generated total revenues of approximately $1.7 million, a net increase of $0.2 million compared to the same period in 2025, primarily driven by collaboration revenue from a new research agreement with William Demant Invest A/S (WDI). The company's operating expenses increased to $9.3 million for the quarter, up $1.3 million from the same period in 2025. This increase was mainly due to higher R&D expenses, which rose by $1.1 million to $4.2 million, and G&A expenses, which increased by $0.2 million to $5.1 million. Lineage also announced several operational highlights, including the launch of a new corneal endothelial disease cell therapy program (COR1) and the successful treatment of a second chronic SCI patient in the DOSED study using a novel delivery system. The company's cash position of $53.4 million as of March 31, 2026, is expected to support planned operations into Q2 2028. The company established a Scientific Advisory Board, with Joachim Fruebis, PhD, as its founding member, and appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical. These appointments are expected to provide strategic counsel and enhance the company's clinical development capabilities.

SEC 8-K•5mo ago

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

Lineage Cell Therapeutics scheduled the release of its first quarter 2026 financial results for after the market close on May 12, 2026. Management will conduct a conference call and webcast at 4:30 p.m. Eastern Time to review the quarterly results and provide a business update. The company is a clinical-stage biotechnology firm developing allogeneic cell therapies, including programs for macular degeneration and spinal cord injuries.

•5mo ago